Vir Biotechnology’s Hepatic Impairment Study: A Potential Game Changer?

Vir Biotechnology, Inc. ((VIR)) announced an update on their ongoing clinical study.

Vir Biotechnology, Inc. is conducting a Phase 1 study titled Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434. The study aims to evaluate the pharmacokinetics, safety, and tolerability of VIR-2218 and VIR-3434, both as monotherapies and in combination, in adults with varying degrees of hepatic impairment, including cirrhosis. This research is significant as it seeks to understand how these drugs behave in patients with liver conditions, potentially informing future treatments.

The study tests two drugs: VIR-2218 and VIR-3434. Both are administered via subcutaneous injection. VIR-2218 is being tested alone and in combination with VIR-3434 to assess their effects on liver-impaired patients.

This interventional study is non-randomized and follows a parallel assignment model. There is no masking involved, and the primary purpose is treatment. The study involves different cohorts based on the severity of hepatic impairment, categorized using the Child-Pugh-Turcotte classification.

The study began on July 15, 2022, and is currently recruiting participants. The primary completion and estimated study completion dates have not been specified, but the last update was submitted on June 10, 2025. These timelines are crucial for tracking the study’s progress and anticipating results.

The study’s progress could influence Vir Biotechnology’s stock performance, as successful outcomes may enhance investor confidence and market position. The study’s results could also impact the competitive landscape, particularly if VIR-2218 and VIR-3434 prove effective for liver conditions.

The study is ongoing, and further details can be found on the ClinicalTrials portal.